Prime Medicine (PRME) Stock Forecast, Price Target & Predictions
PRME Stock Forecast
Prime Medicine stock forecast is as follows: an average price target of $17.25 (represents a 321.76% upside from PRME’s last price of $4.09) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
PRME Price Target
The average price target for Prime Medicine (PRME) is $17.25 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $23.00 to $12.00. This represents a potential 321.76% upside from PRME's last price of $4.09.
PRME Analyst Ratings
According to 5 Wall Street analysts, Prime Medicine's rating consensus is 'Buy'. The analyst rating breakdown for PRME stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Prime Medicine Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 07, 2024 | Maury Raycroft | Jefferies | $15.00 | $5.40 | 177.78% | 266.75% |
| Apr 02, 2024 | David Nierengarten | Wedbush | $12.00 | $6.32 | 89.87% | 193.40% |
| Oct 09, 2023 | Kostas Biliouris | BMO Capital | $19.00 | $8.75 | 117.14% | 364.55% |
| Nov 14, 2022 | - | Morgan Stanley | $23.00 | $21.12 | 8.90% | 462.35% |
The latest Prime Medicine stock forecast, released on May 07, 2024 by Maury Raycroft from Jefferies, set a price target of $15.00, which represents a 177.78% increase from the stock price at the time of the forecast ($5.40), and a 266.75% increase from PRME last price ($4.09).
Prime Medicine Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $15.33 |
| Last Closing Price | $4.09 | $4.09 | $4.09 |
| Upside/Downside | -100.00% | -100.00% | 274.82% |
In the current month, the average price target of Prime Medicine stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prime Medicine's last price of $4.09. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 20, 2024 | H.C. Wainwright | - | Buy | Initialise |
| May 15, 2024 | Citigroup | - | Buy | Upgrade |
| Apr 08, 2024 | Cowen & Co. | - | Buy | Initialise |
| Apr 03, 2024 | Wedbush | Buy | Outperform | Initialise |
| Apr 02, 2024 | Wedbush | - | Buy | Initialise |
| Nov 14, 2022 | Morgan Stanley | - | Equal-Weight | Initialise |
Prime Medicine's last stock rating was published by H.C. Wainwright on May 20, 2024. The company Initialise its PRME rating from "null" to "Buy".
Prime Medicine Financial Forecast
Prime Medicine Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $13.36M | $15.88M | $18.89M | $22.46M | $2.30M | $2.09M | $1.63M | $1.92M | $5.71M | $1.67M |
| High Forecast | $13.36M | $15.88M | $18.89M | $22.46M | $2.30M | $2.09M | $1.63M | $1.92M | $5.71M | $1.67M |
| Low Forecast | $13.36M | $15.88M | $18.89M | $22.46M | $2.30M | $2.09M | $1.63M | $1.92M | $5.71M | $1.67M |
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 3 | 6 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Prime Medicine's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRME's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Prime Medicine EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 3 | 6 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-51.46M |
| Avg Forecast | $2.67M | $3.18M | $3.78M | $4.49M | $460.08K | $418.26K | $326.00K | $384.44K | $1.14M | $333.33K |
| High Forecast | $2.67M | $3.18M | $3.78M | $4.49M | $460.08K | $418.26K | $326.00K | $384.44K | $1.14M | $333.33K |
| Low Forecast | $2.67M | $3.18M | $3.78M | $4.49M | $460.08K | $418.26K | $326.00K | $384.44K | $1.14M | $333.33K |
| Surprise % | - | - | - | - | - | - | - | - | - | -154.38% |
undefined analysts predict PRME's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Prime Medicine's previous annual EBITDA (undefined) of $NaN.
Prime Medicine Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 3 | 6 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | $-50.71M |
| Avg Forecast | $-43.21M | $-42.31M | $-49.17M | $-50.06M | $-51.68M | $-51.18M | $-46.46M | $-54.22M | $-66.27M | $-51.75M |
| High Forecast | $-43.21M | $-42.31M | $-49.17M | $-50.06M | $-51.68M | $-43.03M | $-46.46M | $-54.22M | $-60.74M | $-51.75M |
| Low Forecast | $-43.21M | $-42.31M | $-49.17M | $-50.06M | $-51.68M | $-54.67M | $-46.46M | $-54.22M | $-73.17M | $-51.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.98% |
Prime Medicine's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRME's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Prime Medicine SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 3 | 6 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | $10.49M |
| Avg Forecast | $24.92M | $29.64M | $35.24M | $41.91M | $4.29M | $3.90M | $3.04M | $3.59M | $10.66M | $3.11M |
| High Forecast | $24.92M | $29.64M | $35.24M | $41.91M | $4.29M | $3.90M | $3.04M | $3.59M | $10.66M | $3.11M |
| Low Forecast | $24.92M | $29.64M | $35.24M | $41.91M | $4.29M | $3.90M | $3.04M | $3.59M | $10.66M | $3.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.37% |
Prime Medicine's average Quarter SG&A projection for Dec 23 is $10.66M, based on 6 Wall Street analysts, with a range of $10.66M to $10.66M. The forecast indicates a 1.63% rise compared to PRME last annual SG&A of $10.49M (Sep 23).
Prime Medicine EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 3 | 6 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.55 |
| Avg Forecast | $-0.36 | $-0.35 | $-0.41 | $-0.42 | $-0.43 | $-0.43 | $-0.39 | $-0.45 | $-0.56 | $-0.43 |
| High Forecast | $-0.36 | $-0.35 | $-0.41 | $-0.42 | $-0.43 | $-0.36 | $-0.39 | $-0.45 | $-0.51 | $-0.43 |
| Low Forecast | $-0.36 | $-0.35 | $-0.41 | $-0.42 | $-0.43 | $-0.46 | $-0.39 | $-0.45 | $-0.61 | $-0.43 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.27% |
According to undefined Wall Street analysts, Prime Medicine's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRME previous annual EPS of $NaN (undefined).
Prime Medicine Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RPHM | Reneo Pharmaceuticals | $1.31 | $18.00 | 1274.05% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| NTLA | Intellia Therapeutics | $22.07 | $119.16 | 439.92% | Buy |
| EDIT | Editas Medicine | $3.95 | $17.00 | 330.38% | Buy |
| PRME | Prime Medicine | $4.09 | $17.25 | 321.76% | Buy |
| VERV | Verve Therapeutics | $5.50 | $21.50 | 290.91% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| BEAM | Beam Therapeutics | $26.30 | $64.20 | 144.11% | Buy |
| CRSP | CRISPR Therapeutics | $48.94 | $109.58 | 123.91% | Buy |
| RPRX | Royalty Pharma | $27.72 | $43.33 | 56.31% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
| DNA | Ginkgo Bioworks | $6.32 | $7.34 | 16.14% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
PRME Forecast FAQ
Is Prime Medicine a good buy?
Yes, according to 5 Wall Street analysts, Prime Medicine (PRME) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of PRME's total ratings.
What is PRME's price target?
Prime Medicine (PRME) average price target is $17.25 with a range of $12 to $23, implying a 321.76% from its last price of $4.09. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Prime Medicine stock go up soon?
According to Wall Street analysts' prediction for PRME stock, the company can go up by 321.76% (from the last price of $4.09 to the average price target of $17.25), up by 462.35% based on the highest stock price target, and up by 193.40% based on the lowest stock price target.
Can Prime Medicine stock reach $6?
PRME's average twelve months analyst stock price target of $17.25 supports the claim that Prime Medicine can reach $6 in the near future.
What are Prime Medicine's analysts' financial forecasts?
Prime Medicine's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $7.94M (high $7.94M, low $7.94M), average EBITDA is $1.59M (high $1.59M, low $1.59M), average net income is $-204M (high $-195M, low $-207M), average SG&A $14.82M (high $14.82M, low $14.82M), and average EPS is $-1.708 (high $-1.639, low $-1.737). PRME's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $70.58M (high $70.58M, low $70.58M), average EBITDA is $14.12M (high $14.12M, low $14.12M), average net income is $-185M (high $-185M, low $-185M), average SG&A $131.72M (high $131.72M, low $131.72M), and average EPS is $-1.55 (high $-1.55, low $-1.55).